New England Journal of Medicine· 2014Q1

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

Tomasz M. Beer, Andrew J. Armstrong, Dana E. Rathkopf, Yohann Loriot et al.

3,050citations
Q1SCImago
2014year

Short summary

Enzalutamide, an oral androgen-receptor inhibitor, significantly reduced the risk of radiographic progression by 81% and death by 29% in men with metastatic prostate cancer who had not yet received chemotherapy.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Pulmonary and Respiratory Medicine

Pulmonary and Respiratory MedicineMedicine